trial · primary record
mezigdomide
Relapsed or Refractory Multiple Myeloma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 810 |
| Primary completion | 2033-11-30 |
| Primary endpoint | Progression-free Survival (PFS) |
| Registry ID | NCT05519085 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:40.910Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05519085
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.